Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Mammogram providers are now federally required to tell their patients about their breast density. The new U.S. Food and Drug Administration standards for ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

The Food and Drug Administration issued a rule in March 2023 that requires health care professionals to notify people if they have dense breasts. Studies have shown dense breast tissue can make it ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

New Food and Drug Administration regulations went into effect on Sept ... to receive annual mammograms — X-ray imaging of ...

AWESOME. GREAT INFORMATION. THANK YOU SO MUCH, The Food and Drug Administration now requires all mammogram reports to include a breast density assessment. This is because the risk of breast cancer is ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

Jazz Pharma's diversified drug portfolio drives revenue growth. Zanidatamab shows promise with potential FDA approval in late ...